Q1: What area of law does Hymowitz v. Eli Lilly & Co. primarily address?
Torts (Products Liability; Causation)
Q2: What was the central legal issue in Hymowitz v. Eli Lilly & Co.?
When plaintiffs injured by prenatal exposure to fungible DES cannot identify the specific manufacturer despite diligent efforts, may New York courts apportion liability among DES manufacturers based on their national market shares, and is the legislative revival of otherwise time-barred DES claims constitutional?
Q3: What rule did the court apply?
In DES cases where: (1) the product is fungible and materially indistinguishable across manufacturers; (2) plaintiffs, despite due diligence, cannot identify the specific producer; and (3) DES was marketed generically such that the identification failure is attributable in part to the defendants' market structure and the product's long latency, New York adopts a market-share liability theory. Each defendant is severally liable in proportion to its share of the national DES market for the drug's use in preventing miscarriage during the relevant time. Defendants may exculpate only by proving they did not participate in the DES pregnancy market (e.g., they did not manufacture or market DES for pregnancy use). Liability is several only (no reallocation or joint-and-several liability for absent tortfeasors). Additionally, New York's statutory revival of certain time-barred toxic tort claims is constitutional because revival of limitations periods is a legislative policy judgment rationally related to remedying latent injuries and does not violate due process.
Q4: What was the court's holding?
Yes. The Court of Appeals adopted a national market-share liability approach for DES claims, imposing several, proportionate liability on each defendant according to its share of the national DES pregnancy market, with limited exculpation only for non-participation in that market. The court rejected joint-and-several reallocation of absent market shares. The court also upheld the constitutionality of New York's statute reviving certain time-barred toxic tort claims.
Q5: Why is Hymowitz v. Eli Lilly & Co. significant?
Hymowitz is a cornerstone in torts for understanding how courts address causation when product fungibility and market structures make specific identification impossible. It crystallizes market-share liability as a limited but powerful exception to traditional but-for causation, tightly cabined to DES-like contexts (fungible products, long latency, generic marketing). The case also illustrates judicial tailoring of remedies to balance corrective justice and deterrence with proportional fairness, and it underscores legislative power to revive claims for latent toxic injuries. For students, Hymowitz is essential for analyzing alternative causation doctrines (market share, alternative liability, enterprise liability, concert of action), apportionment of damages, due process limits on innovative tort rules, and the interplay between courts and legislatures in mass tort settings.